No ratings yet
Taught by or worked with Marc? Your rating helps other students choose.
Marc Aucoin is a Professor in the Department of Chemical Engineering at the University of Waterloo. He earned his B.A.Sc. in 2000 and M.A.Sc. in 2003 in Chemical Engineering from the University of Waterloo, followed by a Ph.D. in Chemical Engineering from École Polytechnique de Montréal in 2007. After completing his doctorate, he joined the University of Waterloo as an Assistant Professor in the Department of Chemical Engineering and advanced through the ranks to become a full Professor. He has held several administrative roles, including Academic Director of WatPD Engineering, Associate Chair of Undergraduate Studies, Interim Chair, Associate Chair of Operations, and Acting Chair of the Department of Chemical Engineering. He is a licensed Professional Engineer (PEng) and serves as Director of the Applied Virus and Complex Biologics Bioprocessing Research Lab.
Professor Aucoin specializes in Biochemical Engineering, with a focus on cell culture engineering for the production of complex biologics, including proteins, DNA, virus-like particles, viruses, and viral vectors using insect and mammalian cell platforms. His research interests encompass virus propagation, vaccine production, bioprocess development, and virus stability in complex solutions. He maintains cross-appointments in the Departments of Biology and Chemistry, as well as the Schools of Pharmacy and Optometry at the University of Waterloo. He is an active member of the Centre for Bioengineering and Biotechnology and the Waterloo Centre for Microbial Research. Professor Aucoin has received multiple Faculty of Engineering performance awards, including the Distinguished Performance Award in 2023, 2018, and 2011, and the Outstanding Performance Award in 2022 and 2016. He has contributed to numerous publications on topics such as baculovirus vectors, antiviral coatings, and heterologous protein expression.
Discover University of Waterloo's synthetic biology innovation: engineered Clostridium sporogenes bacteria that infiltrate and eat cancer tumors internally. Promising for pancreatic and solid tumors.
University of Waterloo's engineered Clostridium sporogenes uses quorum sensing to safely colonize and consume solid tumors from within, a major advance in synthetic biology cancer treatments amid 2.1M US cases projected for 2026.
Photo by Precondo CA on Unsplash
Photo by Brecht Corbeel on Unsplash
Photo by Anne Nygård on Unsplash
Photo by Kelly Sikkema on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Philip Strong on Unsplash
